Pre-Market Stock News (October 17, 2007)
(ABBI) Abraxis received two FDA Approvals for Fludarabine Phosphate as cancer drugs.(ABT) Abbott Labs $0.67 EPS vs $0.66 est.(ALGN) Align Tech traded up on positive Cramer comments on Mad Money.(ASYS) Amtech Systems announced $17.4 million in new solar orders; selling…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
(ABBI) Abraxis received two FDA Approvals for Fludarabine Phosphate as cancer drugs.
(ABT) Abbott Labs $0.67 EPS vs $0.66 est.
(ALGN) Align Tech traded up on positive Cramer comments on Mad Money.
(ASYS) Amtech Systems announced $17.4 million in new solar orders; selling $34 million in stock.
(BMY) Bristol-Myers Squibb won FDA approval for Ixempra breast cancer drug for those who have stopped responding to other treatment.
(CIT) CIT Group $1.29 EPS vs $1.24 est.
(CMA) Comerica $1.17 EPS vs $1.22 est.
(CSX) CSX $0.67 EPS vs $0.62 est.
(DLR) Digital Realty Trust priced 3.5 million shares at $39.38 in secondary offering.
(EXAS) EXACT Sciences received Warning Letter from FDA; stock indicated down 10% or more.
(IBM) IBM trading down almost 1% after slightly beating estimates.
(IMCL) ImClone and Bristol-Myers enter pact with Merck KGaA to co-develop ERBITUX in Japan.
(INTC) Intel trading up 5% after beating earnings and raised guidance.
(JPM) JPMorgan Chase $0.97 vs $0.90 est.
(KO) Coca-Cola $0.71 EPS vs $0.68 est.
(LLTC) Linear Tech $0.40 EPS vs $0.38 est.
(MAN) Manpower raised guidance.
(MLAN) Midland gets $65 buyout from Munich RE.
(MO) Altria $1.21 EPS vs $1.14 est.; slightly raised guidance.
(NITE) Knight Trading $0.09 EPS vs $0.12 est.
(PHHM) Palm Harbor -$0.10 EPS vs -$0.05 est.
(SNCI) Sonic traded up on Cramer positive feature on mad Money.
(STX) Seagate traded up almost 2% after beating earnings.
(UTX) United Tech $1.21 EPS vs $1.16 est.
(WBMD) WebMD lowered guidance; stock indicated down as much as 8%.
(YHOO) Yahoo! trading up 9% after beating earnings.
Jon C. Ogg
October 17, 2007
Contact [email protected] for any questions or corrections.
Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.
McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.
His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.
A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.
TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.
McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.
